心房顫動，是一種最常見嚴重持續性心律失常的疾病，它與血栓的發生息息相關。在先前西方國家，為了預防心房顫動所造成的血栓問題，提供了幾個預測血栓的模型，給予臨床醫師瞭解病患的罹患血栓的風險，並施予適當的抗血栓藥物。 其中，最常見的模型為CHADS2。 近日，ACC/AHA/ESC guideline 修改CHADS2 並建立新的模型CHA2DS2-VASc。 CHA2DS2-VASc 在西方族群的準確率比 CHADS2.較佳。 然而，適用於台灣非辦模型病患的模型，目前是未知的。而且抗血栓藥物的使用，對亞洲非瓣膜型心房顫動病患影響的研究，仍然有限。所以根據以上的理由，本篇研究將著重在以下兩點: 第一點,比較抗血栓藥物的使用，在兩個(CHADS2 與CHA2DS2-VASC)模型的在台灣族群之間的差異。 第二點，希望找出適合台灣非辦模型心房顫動病患的預測模型。Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia disorder. It is associated with thromembolism. Several algorithms of risk stratification of thromembolism help clinicians decide the risk and the appropriate antithrombotic treatment in AF patient. One of the most commonly used is the CHADS2 score. More recently, the 2006 ACC/AHA/ESC guideline risk schema evolved into the CHA2DS2-VASc score. The predictive power of CHA2DS2-VASc is better than CHADS2 in the western countries. However, the appropriate model to predict the TE for patients with AF in Taiwan is unknown and the knowledge of the impact of TE related to antithrombotic agents use for AF in Asian is limited.According to the above reasons, this study will focus on these items: first, comparing whether antithrombotic agents use and outcomes differ across CHADS2 and CHA2DS2-VASC risk strata in Taiwan; second, finding an appropriate predicting model for nonvalvular AF patients in Taiwan.
